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Abstract
Background: The Response Evaluation Criteria in Solid Tumors (RECIST) are the current standard for evaluating
disease progression or therapy response in patients with solid tumors. RECIST 1.1 calls for axial, longest-diameter
(or perpendicular short axis of lymph nodes) measurements of a maximum of five tumors, which limits clinicians’
ability to adequately measure disease burden, especially in patients with irregularly shaped tumors. This is especially
problematic in chordoma, a disease for which RECIST does not always adequately capture disease burden because
chordoma tumors are typically irregularly shaped and slow-growing. Furthermore, primary chordoma tumors tend
to be adjacent to vital structures in the skull or sacrum that, when compressed, lead to significant clinical
consequences.
Methods: Volumetric segmentation is a newer technology that allows tumor burden to be measured in three
dimensions on either MR or CT. Here, we compared the ability of RECIST measurements and tumor volumes to
predict clinical outcomes in a cohort of 21 chordoma patients receiving immunotherapy.
Results: There was a significant difference in radiologic time to progression Kaplan-Meier curves between clinical
outcome groups using volumetric segmentation (P = 0.012) but not RECIST (P = 0.38). In several cases, changes in
volume were earlier and more sensitive reflections of clinical status.
Conclusion: RECIST is a useful evaluation method when obvious changes are occurring in patients with chordoma.
However, in many cases, RECIST does not detect small changes, and volumetric assessment was capable of
detecting changes and predicting clinical outcome earlier than RECIST. Although this study was small and
retrospective, we believe our results warrant further research in this area.
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Background
The Response Evaluation Criteria in Solid Tumors
(RECIST) are the current standard for measuring treat-
ment response in patients with malignant solid tumors
[1]. However, RECIST has many limitations. RECIST 1.1,
which calls for measurement of the longest diameter of
the tumor (or perpendicular short axis of malignant
lymph nodes), does not adequately represent the size of
nonspherical lesions, nor does it reflect anisotropic
changes in tumor size. Furthermore, it accounts for only
five tumors per patient, with a maximum of two tumors
per organ system.
The advent of advanced segmentation capabilities in
PACS (Picture Archiving Communications Systems) on
CT and MR has made volumetric segmentation an in-
creasingly common alternative to RECIST. Segmentation
consists of object recognition and delineation for the
purpose of extracting quantitative information, such as
tumor volume [2] and density [3]. It has many advan-
tages over one-dimensional RECIST measurements, in-
cluding the capability to assess all measureable lesions
instead of just five lesions per patient. This has been
shown to decrease variance in assessment of tumor bur-
den [4]. Volumes have also been shown to demonstrate
more consistency than linear measurements in phantoms
(specially designed objects that are scanned to evaluate
imaging technology) [5] and in retrospective studies [6]. It
is thought that volumes better reflect actual changes in
tumor size [7] and better reflect clinical outcomes [8].
Volumetric segmentation has also been shown to be re-
producible, even in complex intracranial tumors [9].
Volumetric assessments may be particularly useful in
certain tumor types. Chordoma is a rare, slow-growing
neoplasm that arises from the remnants of the noto-
chord. Many challenges are associated with chordoma
patient care and research. Because it is a rare disease, lit-
erature about chordoma is scarce. Although it is com-
monly assumed that chordoma does not metastasize
often, recent studies have indicated that it metastasizes
more than previously thought [10]. For this reason, clini-
cians may not look for metastases or may fail to identify
them because metastatic lesions can look like benign
cysts, particularly in the liver [10].
RECIST is especially inadequate for evaluating chor-
doma tumor burden because lesions are generally lobu-
lated and heterogeneous. Furthermore, changes in tumor
size may not be readily detectable by RECIST because of
chordoma tumors’ typically slow growth; however, owing
to the proximity of these tumors to vital structures in
the sacrum and clivus, small changes in size have signifi-
cant clinical consequences. The urgent need for improved
methods of assessing tumor burden in chordoma make




Our cohort consisted of 21 chordoma patients from two
ongoing National Cancer Institute Institutional Review
Board (IRB)–approved phase I clinical trials of thera-
peutic cancer vaccines. Eleven patients received the
yeast-brachyury vaccine GI-6301 (NCT01519817) [11].
Thirteen received MVA-brachyury-TRICOM vaccine
(NCT02179515), three of whom had previously received
the yeast-brachyury vaccine. CT and MR scans were ac-
quired at baseline and during treatment, and patients
who went off trial continued to have follow-up scans.
Patients had 2–14 appointments at which imaging was
done (median, five). Although all patients had surgery
and/or radiation, these treatments were most often given
before the baseline scans. Volumetric segmentations
were done on subsequent scans up through the most re-
cent scan available for each patient. One patient had to
be re-baselined after an ablation for the purpose of our
analysis. As a result, that case is used as two separate
data points (pre- and post-ablation) for radiologic time
to progression (TTP) analysis. Two patients were ex-
cluded for not having at least two time points with CT
and MR, and another patient was excluded because
symptoms recurred after stopping steroids to enroll on a
clinical trial. This resulted in three patients who were
not included in the Kaplan-Meier analysis and one pa-
tient who had two data sets, totaling 19 evaluations. The
two patients without follow-up scans were still included
in other analyses for the purpose of assessing resources
required for volumetric segmentation [12]. This research
was conducted on images collected during two clinical
trials, which were run in compliance with the Helsinki
Declaration and were approved by the Center for Cancer
Research, National Cancer Institute Institutional Review
Board.
Imaging
CT scans of the chest, abdomen, and pelvis were ac-
quired at baseline (pretreatment) and at 8- to 12-week
intervals following treatment initiation using any of the
following scanners: Siemens Definition, Biograph, or
Flash (Siemens Healthcare USA, Malvern, PA), Toshiba
Aquilion ONE™ ViSION CT (Toshiba Medical Systems
Corp., Tochigi, Japan), or GE Lightspeed (GE Medical
Systems, Waukesha, WI).
Patients received contrast-enhanced CT scans using
0.6- to 2.5-mm collimation, 120 kVp, 150–240 reference
mAs (with dose modulation), and 0.25- to 0.75-sec rota-
tion time. Images were pushed to our PACS as contigu-
ous 5 × 5-mm and 2 × 1-mm overlap axial slices for
volumetric assessments and reformats (e.g., coronal).
Scans were obtained with patients coached to full inspir-
ation, supine from chest to pelvis in one acquisition, and
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with weight-based (2 mg/kg) i.v. contrast (Isovue 300 at
2 mL/sec) after a 70-sec delay.
One of the following scanners was used to obtain MR
scans: 3 Tesla (3 T) Verio (Siemens), 3 T Achieva TX
(Philips Healthcare, Andover, MA), 1.5 T Aera (Sie-
mens), 3 T mMR (Siemens), or 1.5 T Achieva (Philips).
Patients received TSE T1 axial and coronal imaging,
TSE T2 axial and coronal imaging with fat suppression
(or STIR), and axial diffusion-weighted imaging with B
values of 0, 250, and 800. Apparent diffusion coefficient
maps were generated from the 0 and 800 B values. All
precontrasted images were acquired at a slice thickness
and imaging gap of 6 × 2 mm.
Prior to contrast administration, a precontrast 3D
Axial T1-weighted sequence (3-mm overlapping VIBE/
DIXON/or E-Thrive) was obtained in a breath-held fash-
ion. Following injection of i.v. gadolinium-based contrast
(0.2 mL/kg, injected at 2 mL/s) (Magnevist®, Schering
AG, Berlin, Germany and MultiHance®, Bracco, Milan,
Italy), postcontrast images were obtained in identical
fashion as the precontrast 3D images. Image acquisition
time points were 20 sec, 70 sec, and a 3-min delay. All
data were automatically subtracted from the precontrast
acquisition. A final postcontrast 3D T1-weighted coronal
image (3-mm overlapping VIBE/DIXON/or E-Thrive)
was obtained at the conclusion of the MR examination.
RECIST measurement
Tumors were evaluated using RECIST 1.1 guidelines [1],
which call for one-dimensional, longest-diameter mea-
surements in the axial plane. A maximum of five lesions
may be evaluated in each patient, with no more than
two per organ system.
Volumetric measurement
A neuroradiologist (NP) reviewed the MR sequences to
determine the best ones to use for segmentation. Post-
contrast scans were not as useful as expected due to
prior radiation and surgical treatments; enhancement
was poor and tumors could not be differentiated from
adjacent structures. Fat-suppressed T2-weighted and
STIR sequences were deemed the most appropriate for
segmenting sacral and paraspinous tumors, whereas
post-contrast FLAIR sequences were used for clival le-
sions. Contrast-enhanced CT sequences were used to
segment all metastases.
A research assistant (KF) performed the segmentations
using the lesion management application within PACS
(Vue PACS v 12.0, Carestream Health, Rochester, NY) as
previously described [12]. In short, the proprietary soft-
ware allows the user to identify the edges of the lesion
with a digital caliper-like tool and then, based on im-
aging characteristics, the software generates a proposed
border for the lesion across all cuts. To do this, the Vue
PACS livewire segmentation tool applies a combination
of fast marching [13] and level set [14] algorithms to-
gether with shape interpolation for region growing. The
cost functions are based on image gradient strengths
and image intensity histograms in order to determine
the expansion limits. The user (KF) can then correct the
border with a correction tool. MR was used for segment-
ing primary tumors and CT for metastatic disease. Bone
metastases were not evaluable by volumetric segmenta-
tion. Tumors with long diameters < 0.5 cm were deemed
immeasurable due to the inherent variability created by
measuring very small lesions, similar to what is outlined
in RECIST 1.1. Masses were reviewed and deemed to be
measurable tumors based on clinical assessment and im-
aging characteristics; not all were biopsy-confirmed.
Radiologist review
A neuroradiologist with 30 years of experience (NP) vali-
dated volumetric segmentations of primary tumors, and
a body radiologist with 20 years of experience (LF) vali-
dated segmented metastatic tumors.
Comparison techniques/statistics
Using the following criteria, we divided patients into two
groups independent from radiologic analysis for TTP.
Patients were placed into either a good or a poor clinical
outcome group, based on the presence (poor) of ≥ 1, or
the absence (good) of all of the following clinical indica-
tors: (1) increasing tumor-related pain requiring signifi-
cant change in pain medications, (2) increasing neurologic
dysfunction, and/or (3) decreasing ECOG performance
status due to tumor-related symptoms [15]. The determin-
ation of clinical outcome was made retrospectively at least
six months after initial imaging studies.
For patients in each category, Kaplan-Meier curves
were used to calculate radiologic TTP by RECIST and by
volume (Fig. 1) using the log-rank test for equality of
survivor functions. A hazard ratio was also calculated
using the Cox proportional hazard regression. TTP by
RECIST was assessed using RECIST 1.1, with progres-
sive disease (PD) being an increase of ≥ 20 % in the sum
of the longest diameters (SLD). TTP by volume was de-
termined based on previously outlined criteria [16],
with PD being an increase of ≥ 40 %. TTP was assessed
based on date of enrollment to time of PD by RECIST
or volumetric criteria. Patient data were censored if PD
criteria were not met on the last imaging studies prior




Our cohort was 85.7 % male (18/21 patients) and had a
median age of 60 (Table 1). Primary tumors were located
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in the spine, sacrum, or clivus, and all patients had been
treated with surgery and/or radiation prior to baseline.
Although only 66.7 % of patients (14/21) were diagnosed
with metastatic disease at baseline, retrospective analysis
identified two additional patients with small metastases
at baseline.
Most patients had 1–5 follow-up appointments (Table 2),
although some had more, and two were excluded from our
analysis for not having at least one follow-up CT and one
follow-up MR that could be analyzed.
A retrospective analysis found that 76.2 % of patients
(16/21) had metastatic disease distributed throughout
the lung, liver, lymph nodes, subcutaneous tissue, and
other soft tissue (Table 3).
Analysis of TTP
Patients in the good clinical outcome group (no poor clin-
ical indicators, n = 12) appeared to have a longer TTP by
volumetric assessment (P = 0.012, HR 0.21, P = 0.02)
than patients in the poor clinical outcome group (≥1 poor
clinical indicators; n = 7). However, there was no differ-
ence between the two groups by RECIST TTP analysis
(P = 0.37, HR 0.52, P = 0.38).
Case studies
Due to small sample size and extensive variability within
our patient population, we found it useful to analyze a
few case studies that exemplified instances in which
volumetric assessment was useful and necessary, as well
a
b
Fig. 1 Volumetric assessment was superior to RECIST at predicting
clinical status in this cohort. a Time to radiologic progression by
volume. Actuarial median for good clinical outcome = 271 days;
median for poor outcome = 156 days; P = 0.012; HR for good vs.
poor clinical status = 0.21, P = 0.023. b Time to radiologic progression
by RECIST. Actuarial median for good clinical outcome = 271 days;
median for poor outcome = 167 days; P = 0.37; HR for good vs. poor
clinical status = 0.52, P = 0.38
Table 1 Patient demographics




Prior treatment # (%)
Surgery 20 (95.2)
Radiation 20 (95.2)
Primary tumor # (%)
Lumbar/sacral spine 14 (66.7)
Clivus 6 (28.6)
Cervical spine 1 (4.8)
Metastatic disease at baseline # (%)
Yes 14 (66.7)
No 7 (33.3)
Table 2 Number of follow-up appointments with≥ 1 CT or 1
MR/patient




CT computed tomography, MR magnetic resonance
Table 3 Distribution of metastases at baseline and most recent
follow-up
Location of metastases # of patients (%)a
at baseline
# of patients (%)a at
most recent follow-up
Lung 9 (56.3) 10 (62.5)
Liver 9 (56.3) 9 (56.3)
Lymph nodes 2 (12.5) 5 (31.3)
Subcutaneous 4 (25.0) 4 (25.0)
Other soft tissue 5 (31.3) 6 (37.5)
Total # of patients
with metastases
16 (100.0) 16 (100.0)
aPercentages based on 16 patients found to have metastases. Eleven patients
(68.8 %) had bone metastases, which were not evaluable by volumetric
segmentation. Values were obtained by retrospective analysis; thus two
patients with unnoticeable metastatic disease at baseline are included
Fenerty et al. BMC Cancer  (2016) 16:672 Page 4 of 9
as instances in which RECIST provided sufficient infor-
mation about tumor burden.
Case 1
For patients who did very well or very poorly clinically,
RECIST was often sufficient to illustrate the extent of
their disease, while volumes provided little additional in-
formation. For one patient with recurrent pelvic masses
who had done well clinically for over 2 years, RECIST
indicated a partial response (–43.9 %) and volume indi-
cated a minor response (–59.9 %). On July 8, 2013, the
RECIST measurement for the patient’s primary lesion
was 6.0 cm and its volume was 39.8 cm3. By January 6,
2015, the lesion measured 5.2 cm by RECIST and 14.1 cm3
by volume (Fig. 2). In cases where progression or response
is less apparent, volumes may be superior to RECIST in
predicting clinical outcome (see cases 2 to 4 below).
Case 2
One patient had severe pain that increased while on treat-
ment and became difficult to manage by the restaging visit
at 12 weeks. Based on that rapid progression of symptoms,
the patient was retrospectively classified in the poor clin-
ical outcome group. Axial measurement of the longest
diameter of the presacral/pelvic tumor mass demonstrated
growth that did not meet progression criteria (RECIST
Fig. 2 a Patient with a pelvic mass for whom RECIST is an adequate measure of tumor burden, and volumetric measurement provides little additional
information. At the most recent follow-up appointment, RECIST indicated a partial response (–43.9 %) and volume indicated a minor response
(–59.9 %). b Volumetric measurement of the patient’s primary lesion. c Six months later, the tumor had shrunk by both RECIST and volume
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+17.2 %). However, the symptoms were consistent with
significant tumor growth, which was observed volumetric-
ally (+139 %), with the most notable growth in the cranial-
caudal axis (Fig. 3).
Case 3
In other patients, volume indicated PD earlier than
RECIST. In one patient with metastatic disease to the
liver and lungs, PD was identified at the 28-week follow-
up by volume (+71.4 %), but not until the 36-week
follow-up by RECIST (+23.9 %) (Fig. 4). In cases such as
these, using total tumor volume as a metric of disease
progression would allow patients to consider alternative
therapies earlier.
Case 4
It can be difficult to determine the projected clinical
course for a patient with chordoma for whom RECIST
indicates almost no change over extended periods of
time. For one patient with clival chordoma, RECIST
showed an increase of 5 %, whereas volume indicated a
decrease of 32.4 %. On July 9, 2013, the patient’s primary
lesion measured 2.1 cm by RECIST and 10.6 cm3 by vol-
ume. By May 26, 2015, the lesion still measured 2.1 cm
by RECIST but only 7.1 cm3 by volume (Fig. 5). The
patient is doing well clinically, with subjective improve-
ments in headaches related to the tumor mass.
Discussion
Because our clinical experience indicated changes in symp-
toms prior to radiologic progression by RECIST, we sought
to identify a tool that would give us an earlier insight into
the trajectory of a given patient’s tumor. We noted a recur-
ring pattern of tumor growth in imaged sections of tumors
that were not those with the longest dimension. This find-
ing led to the hypothesis that the total tumor volume may
be changing despite lack of obvious change in the longest
dimension, as measured by RECIST. Volumetric assess-
ment of tumors has previously been difficult to perform.
Radiation oncologists have used planning software to as-
sess volume with promising results [17], but we wanted to
determine if measuring volume could be more widely insti-
tuted. Recent improvements in imaging software have
allowed for semi-automated assessment of total tumor vol-
ume. Volume assessment is still labor-intensive, but that
limitation appears to be improving rapidly.
Conclusions
In this hypothesis-generating study, we demonstrated
the feasibility of using volumetric assessments and their
Fig. 3 a Patient with a large presacral/pelvic mass had progressed by volume at 12-week follow-up (+139 %) but not by RECIST (+17.2 %). b 3D
rendering of the patient’s lesion at baseline better illustrates tumor size and shape. c Three months later, the tumor had undergone drastic
anisotropic growth not detectable by RECIST
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Fig. 5 Patient with clival chordoma who seems to be experiencing clinical benefit from treatment. a At the most recent follow-up, volume is
trending toward improvement (–32.4 %), whereas RECIST measurements have barely changed (+5.0 %). b The patient’s primary lesion. c Twenty-two
months later, the patient’s RECIST measurement had not changed. The tumor was smaller by volume but had not yet reached a partial response by
volumetric criteria
Fig. 4 A case of metastatic disease to the liver and lungs in which volume indicated progressive disease earlier than RECIST. a PD was identified
at 28-week follow-up by volume (+71.4 %), but not until 36-week follow-up by RECIST (+23.9 %). b A 3D rendering of this patient's tumors dem-
onstrates the potential importance of measuring total tumor volume to determine treatment effect
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potential impact on clinical decision-making. There were
clear limitations to this study. First, we retrospectively
applied a new, nonvalidated definition for clinical out-
comes to a retrospective data set. Second, in this rela-
tively small data set there was significant heterogeneity
of tumor locations (sacral vs. spine vs. clival vs. meta-
static disease). Third, the accuracy of measurements var-
ied among our various imaging techniques. And finally,
we used a 40 % cut-off for progression using volumetric
assessment, which is not validated and was created
based on different methods than we used in this study.
These limitations preclude drawing definitive conclu-
sions from the results. The use of clinical criteria retro-
spectively is perilous due to the possibility of bias
influencing the outcomes. However, the clinical outcome
groups were determined prior to the volumetric assess-
ment and comparison to RECIST, limiting this concern.
The heterogeneity of tumor locations is a major reason
for the need to identify better imaging methods for chor-
doma and represents the nature of research in this rare
disease. The potential variability between scans is an
issue present in both RECIST measurement [18] and
volumetric measurement, but is likely to be more pro-
nounced on a single cut than over many cuts encom-
passing the entire tumor mass. Our choice of a cut-off
for significant change by volume is based on a study
evaluating volume by different methods, but we believe
the rationale for this choice remains reasonable. Despite
these weaknesses, the data presented here support the
hypothesis that volumetric assessment may be a more
sensitive tool for measuring early tumor progression in
chordoma and suggest that further exploration of this
method is worthwhile. For cases in which RECIST meas-
urement demonstrates growth or regression, volumetric
assessment is probably unnecessary and unlikely to have
a significant impact. Volumetric assessment appears to
be most useful in cases where RECIST can detect no dis-
cernable change in tumor size.
In chordoma management, small changes in tumor
size may have significant clinical impacts due to the ana-
tomic location of lesions. Cases 2, 3, and 4 presented
here illustrate situations in which small changes in
RECIST measurement may belie more significant growth
in other dimensions. Patients were retrospectively
grouped into good or poor clinical outcome categories
based on relatively simple criteria. When we compared
TTP in these groups by RECIST, we found no differ-
ences (P = 0.37, HR 0.52, P = 0.38). However, when we
compared TTP by volumetric measurement, there was a
clear separation of the curves (P = 0.012, HR 0.21, P = 0.02).
While not definitive, these preliminary findings support our
hypothesis that volumetric tumor assessment is a more sen-
sitive tool for evaluating tumor growth in chordoma, and
may be useful for predicting clinical outcomes in patients
for whom RECIST demonstrates no change. Based on these
findings, we suggest that clinical trials in chordoma should
employ volumetric tumor assessment to determine the
feasibility of real-time measurement and the potential im-
pact on prospective clinical decisions.
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